EcoDrugPlus

Dopamine Receptor D3

Ensembl ID : ENSLCAG00010012019
Gene Symbol: LOC108881734
4 Cross references
203 Possible Orthologues:

Dopamine Receptor D4b

Ensembl ID : ENSLCAG00010004248
Gene Symbol: LOC108894166
4 Cross references
181 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSLCAG00010001062
Gene Symbol: ENPP2
1 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSLCAG00010004788
Gene Symbol: EGLN1
4 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSLCAG00010018876
Gene Symbol: EGLN2
3 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSLCAG00010005126
Gene Symbol: LOC108881163
4 Cross references
197 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSLCAG00010002330
Gene Symbol: EPAS1B
4 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSLCAG00010010767
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSLCAG00010019419
Gene Symbol: EDNRAA
1 Cross references
205 Possible Orthologues:

Endothelin Receptor Type Ab

Ensembl ID : ENSLCAG00010022118
Gene Symbol: EDNRAB
1 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSLCAG00010006604
Gene Symbol: EDNRB
1 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSLCAG00010003973
Gene Symbol: EDNRB
4 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).